Lung Cancer

Glendale, AZ

164 Lung Cancer Trials near Glendale, AZ

Power is an online platform that helps thousands of Lung Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Radiation + Immunotherapy for Non-Small Cell Lung Cancer

Phoenix, Arizona
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

427 Participants Needed

GMCI + Immunotherapy for Lung Cancer

Phoenix, Arizona
The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. A combination of CAN-2409 added to standard of care (SOC) checkpoint inhibitors may lead to improved long-term outcomes for patients with NSCLC who have suboptimal response to ICI therapy.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

90 Participants Needed

Pembrolizumab Combo for Lung Cancer

Tempe, Arizona
This trial is testing different combinations of cancer drugs to find the best treatment for patients with advanced lung cancer who haven't been treated before. The drugs help the immune system fight cancer or stop the cancer cells from growing.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

318 Participants Needed

Erlotinib + Cabozantinib for Non-Small Cell Lung Cancer

Scottsdale, Arizona
This randomized phase II trial studies how well giving erlotinib hydrochloride and cabozantinib-s-malate alone or in combination works as second or third line therapy in treating patient with stage IV non-small cell lung cancer. Erlotinib hydrochloride and cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving erlotinib hydrochloride together with cabozantinib-s-malate is more effective than erlotinib hydrochloride or cabozantinib-s-malate alone in treating non-small cell lung cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

125 Participants Needed

PF-07248144 for Breast Cancer

Scottsdale, Arizona
This trial is testing a new cancer drug called PF-07248144. It aims to find the best dose and see if it works better alone or with other cancer drugs. The study focuses on cancer patients who may not be responding well to current treatments.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

320 Participants Needed

Immunotherapy Combo for Lung Cancer

Phoenix, Arizona
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting

860 Participants Needed

Chemotherapy + Bevacizumab for Non-Small Cell Lung Cancer

Scottsdale, Arizona
This randomized phase III trial studies chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether chemotherapy is more effective with or without bevacizumab in treating non-small cell lung cancer.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

1501 Participants Needed

MRT-2359 for Solid Tumors

Scottsdale, Arizona
This trial tests a new drug called MRT-2359 that breaks down a protein in cancer cells. It targets patients with certain types of previously treated cancers. The drug aims to destroy a protein crucial for cancer cell survival, potentially stopping or slowing the cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

174 Participants Needed

GEN1046 for Cancer

Phoenix, Arizona
The goal of this trial is to learn about the antibody acasunlimab (an antibody also known as GEN1046) when it is used alone and when it is used together with standard of care treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of patients with certain types of cancer. All subjects will receive active drug; no one will receive placebo. This trial has 2 parts. The purpose of the first part is to find out if acasunlimab is safe and to find out the best doses of acasunlimab to use. The purpose of the second part is to give acasunlimab to more subjects to see how well the doses of acasunlimab selected in the first part work against cancer when given alone and how well they work when given with pembrolizumab (with or without other chemotherapy) or docetaxel. Trial details include: * The average trial duration for an individual subject will be about 74 weeks. * The average treatment duration for an individual subject will be about 21 weeks. * The visit frequency will be weekly at first and lessening over time until visits are only once every 3 weeks.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

429 Participants Needed

BMF-219 for Lung Cancer

Goodyear, Arizona
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
No Placebo Group

Trial Details

Trial Status:Recruiting

90 Participants Needed

KB707 for Lung Cancer

Scottsdale, Arizona
The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector that is designed to stimulate an anti-tumor immune response through the production of cytokines delivered to the airways of people with advanced solid tumor malignancies affecting the lungs via nebulization. This Phase 1/2, open-label, multicenter, dose escalation and expansion study is designed to evaluate the safety and tolerability of KB707 in adults with with advanced solid tumor malignancies affecting the lungs who have progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy, as well as the safety, tolerability, preliminary efficacy, and immunologic effect of KB707 administered in combination with Keytruda, with or without chemotherapy, to subjects with advanced NSCLC. The study will include a dose escalation portion for single agent KB707 using a standard 3+3 design followed by a dose expansion portion to further evaluate single agent KB707 at a dose determined by preliminary data in the dose escalation phase. Subjects in the dose escalation (Cohorts 1 and 2) and dose expansion (Cohort 4) will receive KB707 via nebulization weekly for three weeks, then every three weeks. The dose escalation portion of the study has now closed, and the Cohort 2 dose was selected for evaluation in dose expansion. Dose expansion Cohorts 5 and 6 will evaluate subjects with advanced non-small cell lung cancer (NSCLC). Subjects in Cohorts 5 and 6 will receive inhaled KB707 per treatment day once every 2 weeks (q2w), delivered in combination with Keytruda (once every 6 weeks). All subjects will be treated until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

200 Participants Needed

Autogene Cevumeran + Atezolizumab for Cancer

Scottsdale, Arizona
This trial tests a personalized cancer vaccine and an immune-boosting drug in cancer patients. The vaccine teaches the body to attack cancer, while the drug helps immune cells find and kill hidden cancer cells. This approach aims to induce strong anti-tumor responses by selecting suitable vaccines based on the patient's existing immune system.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

272 Participants Needed

LP-300 + Chemotherapy for Lung Adenocarcinoma EGFR

Goodyear, Arizona
This trial tests a new drug, LP-300, combined with two existing chemotherapy drugs in never smokers with a specific type of lung cancer who did not respond to previous treatments. The goal is to see if this combination improves survival by making the chemotherapy more effective.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

90 Participants Needed

LY4170156 for Breast Cancer

Scottsdale, Arizona
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

360 Participants Needed

Sonidegib + Pembrolizumab for Advanced Cancers

Scottsdale, Arizona
This trial tests the best dose of sonidegib combined with pembrolizumab for treating advanced solid tumors. Sonidegib blocks enzymes needed for tumor growth, while pembrolizumab helps the immune system attack cancer. The study focuses on patients with advanced cancers that have spread, aiming to find a more effective treatment than standard options.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

36 Participants Needed

IMM-6-415 for Solid Tumors

Scottsdale, Arizona
This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

240 Participants Needed

PRO1107 for Advanced Cancer

Scottsdale, Arizona
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

42 Participants Needed

MRTX1719 for Solid Tumors

Phoenix, Arizona
This trial is testing a new drug, MRTX1719, for patients with advanced cancers that have a specific genetic deletion. The drug aims to kill cancer cells by exploiting a weakness caused by this genetic change.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

320 Participants Needed

JAB-21822 + Cetuximab for Solid Tumors

Phoenix, Arizona
This trial is testing a new drug, JAB-21822, alone and with cetuximab in adults with advanced cancers that have a specific genetic change called KRAS G12C. The goal is to see if these treatments are safe and can stop the cancer from growing. Adagrasib is a related molecule that also has FDA approval for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

100 Participants Needed

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody for Advanced Cancer

Scottsdale, Arizona
This trial is testing two new drugs that help the immune system fight cancer. It targets adults with advanced cancers that haven't responded to other treatments. The drugs work by blocking proteins that usually prevent the immune system from attacking cancer cells.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

499 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

OF
Cholangiocarcinoma PatientAge: 54

"I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."

UM
Pancreatic Cancer PatientAge: 48

"I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

EQ
Lung Cancer PatientAge: 70

"I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

FR
Lung Cancer PatientAge: 71

IMM-1-104 for Solid Cancers

Scottsdale, Arizona
This trial is testing a new drug called IMM-1-104 to see if it can help treat advanced cancers with specific genetic changes. The drug works by blocking signals that make cancer cells grow.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

320 Participants Needed

GD2-SADA:177Lu-DOTA Complex for Small Cell Lung Cancer

Scottsdale, Arizona
This trial tests a new treatment for certain cancers using a two-part method. The first part finds and attaches to cancer cells, and the second part delivers radiation to kill them. It aims to see if this treatment is safe and can be tolerated by patients with Small Cell Lung Cancer, Sarcoma, and Malignant Melanoma.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:16+

60 Participants Needed

Dabrafenib + Trametinib Access for Cancer

Scottsdale, Arizona
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

100 Participants Needed

RP1 + Nivolumab for Cancer

Phoenix, Arizona
This trial tests a modified virus (RP1) and an immune-boosting drug (nivolumab) in adults with advanced or treatment-resistant solid tumors. RP1 kills cancer cells and helps the immune system recognize them, while nivolumab enhances the immune response. Nivolumab has been approved for treating advanced melanoma, renal cell carcinoma, non-small cell lung cancer, and other malignancies.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

340 Participants Needed

CM24 + Nivolumab for Solid Tumors

Scottsdale, Arizona
This trial tests a combination of new and existing drugs to treat patients with severe forms of cancer. The treatment aims to boost the immune system's ability to fight cancer and directly kill cancer cells.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

79 Participants Needed

ST-067-001 for Solid Tumors

Scottsdale, Arizona
This trial is testing a new drug called ST-067 on patients with certain types of cancer that have not responded to previous treatments. The goal is to find the safest and most effective dose and to see how well it works against these cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

316 Participants Needed

CLSP-1025 for Cancer

Scottsdale, Arizona
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

90 Participants Needed

AB308 + Zimberelimab for Advanced Cancers

Phoenix, Arizona
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

94 Participants Needed

XL092 + Immuno-Oncology Agents for Solid Tumors

Phoenix, Arizona
This trial is testing a new drug called XL092 alone and with other cancer drugs in patients with advanced solid tumors. The goal is to see if these treatments can safely stop or slow tumor growth and help the immune system fight cancer more effectively.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

1274 Participants Needed

Cabozantinib for Pancreatic Neuroendocrine Tumors

Phoenix, Arizona
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

298 Participants Needed

123456

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Lung Cancer clinical trials in Glendale, AZ pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Lung Cancer clinical trials in Glendale, AZ work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Lung Cancer trials in Glendale, AZ 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Glendale, AZ for Lung Cancer is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Glendale, AZ several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Lung Cancer medical study in Glendale, AZ?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Lung Cancer clinical trials in Glendale, AZ?

Most recently, we added Multiple Treatments for Non-Small Cell Lung Cancer, A2B395 CAR T-Cell Therapy for Colorectal Cancer and CLSP-1025 for Cancer to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Arizona

Anxiety Clinical Trials in Arizona

Schizophrenia Clinical Trials in Arizona

ADHD Clinical Trials in Arizona

Bipolar Disorder Clinical Trials in Arizona

Multiple Sclerosis Clinical Trials in Arizona

Autism Clinical Trials in Arizona

Treatment Resistant Depression Clinical Trials in Arizona

Borderline Personality Disorder Clinical Trials in Arizona

Social Anxiety Disorder Clinical Trials in Arizona

Parkinson's Disease Clinical Trials in Arizona

Alzheimer's Disease Clinical Trials in Arizona

By Location

Clinical Trials near Phoenix, AZ

Clinical Trials near Tucson, AZ

Clinical Trials near Scottsdale, AZ

Clinical Trials near Mesa, AZ

Clinical Trials near Chandler, AZ

Clinical Trials near Tempe, AZ

Clinical Trials near Gilbert, AZ

Clinical Trials near Glendale, AZ

Clinical Trials near Peoria, AZ

Clinical Trials near Sun City, AZ

Clinical Trials near Goodyear, AZ

Clinical Trials near Flagstaff, AZ

Other People Viewed

By Subject

Top Colorectal Cancer Clinical Trials near Glendale, AZ

Top Clinical Trials near Glendale, AZ

Top Breast Cancer Clinical Trials near Glendale, AZ

Top Prostate Cancer Clinical Trials near Glendale, AZ

Top Lung Cancer Clinical Trials near Phoenix, AZ

201 Clinical Paid Trials near Glendale, AZ

12 Weight Loss Trials near Glendale, AZ

43 Glioblastoma Trials near Glendale, AZ

Top Colorectal Cancer Clinical Trials near Phoenix, AZ

Top Breast Cancer Clinical Trials near Phoenix, AZ

Top Prostate Cancer Clinical Trials near Phoenix, AZ

Top Lung Cancer Clinical Trials near Philadelphia, PA

By Trial

Cryosurgery for Early Stage Lung Cancer

Chemotherapy + High-Dose Radiation for Lung Cancer

Trametinib + Pembrolizumab for Lung Cancer

Exercise and Counseling for Lung Cancer Prevention

AI-Directed Radiation Therapy for Lung Cancer

Project PEER: Understanding the Lung Cancer Patient ExperiEnce

Vitamin C for Lung Cancer

Pembrolizumab for Lung Cancer

BNT327 + Chemotherapy for Lung Cancer

LungTalk for Increasing Lung Cancer Screening

Datopotamab Deruxtecan + Immunotherapy for Non-Small Cell Lung Cancer

MK-7684A + Chemotherapy for Lung Cancer

Related Searches

Top Lung-cancer Clinical Trials near Los Angeles, CA

Top Lung-cancer Clinical Trials near Baltimore, MD

Top Clinical Trials near Miami, FL

Top Clinical Trials near Boston, MA

Pre-Surgical Radiosurgery for Brain Metastases

SinuSonic for Sinus Headache

WATCHMAN Device for Atrial Fibrillation

Self-Removal of Catheters After Urogynecologic Surgery

Post-Surgery Walking Program for Lung Cancer

Allodepleted T Cells for Leukemia

PCNA Inhibitor AOH1996 for Cancer

Cemiplimab + ISA101b for HPV-Related Throat Cancer

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial